Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2024 · 10-Q
Revenue$53.00K$53.00K−97.3% vs Q1 2023 Net Income-$2.54M-$2.54MN/M vs Q1 2023 EPS Diluted-$1.54-$1.54no prior Q1 2023 on file Operating Income-$1,759,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,102,000N/M Margins · derivedOperating margin-3318.9%−2517.7 pt vs Q1 2023
Net margin-4784.9%−4104.0 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end